Which has stronger valuation & earnings, TARA or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A

Is TARA or OLMA more profitable?

Protara Therapeutics' return on equity of -41.72% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media refer more to TARA or OLMA?

In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 2 mentions for Protara Therapeutics. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Protara Therapeutics' score of 0.81 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TARA or ANL?

Adlai Nortye has higher revenue and earnings than Protara Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A Adlai Nortye $18.06M 54.25 -$35.53M N/A N/A

Is TARA or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Adlai Nortye N/A N/A N/A

Does the media refer more to TARA or ANL?

In the previous week, Adlai Nortye had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Adlai Nortye and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat Adlai Nortye's score of 0.51 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TARA or FTH?

Protara Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.35 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is TARA or FTH more profitable?

Protara Therapeutics' return on equity of -41.72% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media favor TARA or FTH?

In the previous week, Sensei Biotherapeutics had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Sensei Biotherapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat Sensei Biotherapeutics' score of 0.58 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARA or RIGL?

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 2 mentions for Protara Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat Protara Therapeutics' score of 0.81 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TARA or DBVT?

In the previous week, DBV Technologies had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Protara Therapeutics. DBV Technologies' average media sentiment score of 1.07 beat Protara Therapeutics' score of 0.81 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protara Therapeutics (TARA) Competitors

$3.82 +0.03 (+0.79%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.08 (+2.09%)

As of 09/11/2026 07:30 PM Eastern

Compare

TARA vs. OLMA, ANL, FTH, RIGL, and DBVT

Should you buy Protara Therapeutics stock or one of its competitors? Protara Therapeutics's main competitors and comparable companies include Olema Pharmaceuticals (OLMA), Adlai Nortye (ANL), Sensei Biotherapeutics (FTH), Rigel Pharmaceuticals (RIGL), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Protara Therapeutics (NASDAQ:TARA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Protara Therapeutics' return on equity of -41.72% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Protara Therapeutics. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 2 mentions for Protara Therapeutics. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Protara Therapeutics' score of 0.81 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 587.17%. Olema Pharmaceuticals has a consensus target price of $42.40, indicating a potential upside of 314.87%. Given Protara Therapeutics' higher probable upside, research analysts clearly believe Protara Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Protara Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Olema Pharmaceuticals beats Protara Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Protara Therapeutics compare to Adlai Nortye?

Protara Therapeutics (NASDAQ:TARA) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Protara Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Adlai Nortye has higher revenue and earnings than Protara Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Adlai Nortye	$18.06M	54.25	-$35.53M	N/A	N/A

In the previous week, Adlai Nortye had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Adlai Nortye and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat Adlai Nortye's score of 0.51 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Adlai Nortye	N/A	N/A	N/A

Protara Therapeutics currently has a consensus price target of $26.25, suggesting a potential upside of 587.17%. Adlai Nortye has a consensus price target of $29.50, suggesting a potential upside of 93.95%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protara Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Protara Therapeutics beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.

How does Protara Therapeutics compare to Sensei Biotherapeutics?

Protara Therapeutics (NASDAQ:TARA) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Sensei Biotherapeutics had 7 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Sensei Biotherapeutics and 2 mentions for Protara Therapeutics. Protara Therapeutics' average media sentiment score of 0.81 beat Sensei Biotherapeutics' score of 0.58 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics' return on equity of -41.72% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Protara Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Protara Therapeutics currently has a consensus target price of $26.25, suggesting a potential upside of 587.17%. Sensei Biotherapeutics has a consensus target price of $55.00, suggesting a potential upside of 46.90%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Protara Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

Summary

Protara Therapeutics beats Sensei Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Protara Therapeutics compare to Rigel Pharmaceuticals?

Protara Therapeutics (NASDAQ:TARA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Protara Therapeutics currently has a consensus target price of $26.25, indicating a potential upside of 587.17%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 24.89%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 2 mentions for Protara Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat Protara Therapeutics' score of 0.81 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 116.30% compared to Protara Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Protara Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has higher revenue and earnings than Protara Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
Rigel Pharmaceuticals	$276.79M	3.16	$367.02M	$16.32	2.89

Summary

Rigel Pharmaceuticals beats Protara Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Protara Therapeutics compare to DBV Technologies?

Protara Therapeutics (NASDAQ:TARA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Protara Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, indicating that its stock price is 195% less volatile than the broader market.

Protara Therapeutics has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A

Protara Therapeutics presently has a consensus price target of $26.25, suggesting a potential upside of 587.17%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 309.28%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Protara Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, DBV Technologies had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Protara Therapeutics. DBV Technologies' average media sentiment score of 1.07 beat Protara Therapeutics' score of 0.81 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protara Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Protara Therapeutics' return on equity of -41.72% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Summary

Protara Therapeutics beats DBV Technologies on 11 of the 15 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARA vs. The Competition

Export

Metric	Protara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$223.97M	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-2.83	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.01	15.12	10.33	6.20
Net Income	-$57.44M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.05%	-4.34%	-3.32%	-2.35%
1 Month Performance	-1.80%	-0.02%	-0.41%	-2.77%
1 Year Performance	21.66%	40.64%	19.21%	7.63%

Protara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARA Protara Therapeutics	1.8196 of 5 stars	$3.82 +0.8%	$26.25 +587.2%	+19.4%	$223.97M	N/A	N/A	30
OLMA Olema Pharmaceuticals	2.6969 of 5 stars	$10.43 +1.6%	$42.40 +306.5%	+27.8%	$898.60M	N/A	N/A	70	News Coverage Positive News
ANL Adlai Nortye	2.1716 of 5 stars	$14.19 +2.7%	$24.25 +70.9%	+745.0%	$889.98M	$5M	N/A	127	News Coverage Analyst Forecast
FTH Sensei Biotherapeutics	4.1424 of 5 stars	$32.77 -3.2%	$55.00 +67.8%	N/A	$874.44M	N/A	N/A	40	News Coverage Analyst Forecast
RIGL Rigel Pharmaceuticals	4.5911 of 5 stars	$46.18 -0.6%	$59.00 +27.8%	+24.9%	$859.98M	$294.28M	2.83	160	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protara Therapeutics (TARA) Competitors

TARA vs. OLMA, ANL, FTH, RIGL, and DBVT

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Protara Therapeutics compare to Adlai Nortye?

Summary

How does Protara Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Protara Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protara Therapeutics (TARA) Competitors

TARA vs. OLMA, ANL, FTH, RIGL, and DBVT

How does Protara Therapeutics compare to Olema Pharmaceuticals?

Which has stronger valuation & earnings, TARA or OLMA?

Is TARA or OLMA more profitable?

Does the media refer more to TARA or OLMA?

Do analysts prefer TARA or OLMA?

Which has more volatility and risk, TARA or OLMA?

Do insiders & institutionals believe in TARA or OLMA?

Summary

How does Protara Therapeutics compare to Adlai Nortye?

Which has more risk and volatility, TARA or ANL?

Which has preferable earnings and valuation, TARA or ANL?

Does the media refer more to TARA or ANL?

Is TARA or ANL more profitable?

Do analysts prefer TARA or ANL?

Do insiders & institutionals hold more shares of TARA or ANL?

Summary

How does Protara Therapeutics compare to Sensei Biotherapeutics?

Does the media favor TARA or FTH?

Is TARA or FTH more profitable?

Which has higher earnings and valuation, TARA or FTH?

Do analysts rate TARA or FTH?

Do insiders and institutionals have more ownership in TARA or FTH?

Which has more risk & volatility, TARA or FTH?

Summary

How does Protara Therapeutics compare to Rigel Pharmaceuticals?

Do analysts rate TARA or RIGL?

Does the media favor TARA or RIGL?

Is TARA or RIGL more profitable?

Which has more risk and volatility, TARA or RIGL?

Do insiders & institutionals hold more shares of TARA or RIGL?

Which has stronger earnings and valuation, TARA or RIGL?

Summary

How does Protara Therapeutics compare to DBV Technologies?

Which has more risk & volatility, TARA or DBVT?

Which has better earnings and valuation, TARA or DBVT?

Do analysts rate TARA or DBVT?

Does the media refer more to TARA or DBVT?

Do institutionals & insiders have more ownership in TARA or DBVT?

Is TARA or DBVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA vs. The Competition

Protara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools